BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

"This partnership will enable us to leverage Antitope's unique technology in generating our therapeutic vaccines which may represent a genuinely novel approach to treating those diseases having a major unmet medical need," said Jacques Banchereau, director of the Baylor Institute for Immunology Research (BIIR), the human immunology department of BRI.

"This research is integrated within the ANRS HIV vaccine research program aimed to develop innovative strategies towards a preventive and/or therapeutic vaccine," said PR Yves Levy, the scientific director of the ANRS HIV Vaccine network.